Future medicines could fail 1.5 billion Africans – this founder won’t let that happen
- Ayodeji Alaran believes that Africa's innovation should stem from academic research and deep science.
- Alaran's early career included responsibilities at GlaxoSmithKline, where he wrote policies for Ghana and Nigeria.
- He transitioned to Pfizer, where he learned to sell medicine using data and clinical evidence.
Alaran's approach to integrating scientific research with entrepreneurial ventures in Africa's healthcare sector is commendable. It highlights the importance of data-driven decision-making in improving health outcomes, yet it raises questions about the scalability of such initiatives and the need for broader infrastructure support across the continent.
